StocksMedium•6 November 2026•
1 min read
Inspire Medical Systems Gains FDA Approval for Pediatric Down Syndrome Patients
Key Facts
1Inspire Medical Systems received FDA approval to offer its neurostimulation therapy to pediatric patients with Down syndrome.
Inspire Medical Systems received FDA approval to offer its neurostimulation therapy to pediatric patients with Down syndrome. Benzinga reported that the approval expands the application of the company's technology to include children suffering from obstructive sleep apnea.
The regulatory milestone increases the total addressable market for Inspire Medical Systems by addressing a specific demographic with high clinical needs. INSP closed at $66.53 on November 5, 2026, with the stock trading between a day low of $64.81 and a day high of $68.95 during that session.